Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Weight Loss Response to Liraglutide via fMRI
NCT03795701Completed
- Sponsor
- Texas Tech University
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity comparing Liraglutide 3.0 with Placebo (2 arms). Primary endpoints: Pre-prandial functional Magnetic Resonance Imaging Food Cue Reactivity at Week 16, Post-prandial functional Magnetic Resonance Imaging Food Cue Reactivity at Week 16 and 4 more. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03795701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795701.